PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
6.19%
Revenue growth of 6.19% vs. zero growth in Medical - Pharmaceuticals. Walter Schloss might still want to see if it can translate into profits.
2.25%
Gross profit growth of 2.25% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight advantage that could be built upon.
4.51%
EBIT growth of 4.51% while Medical - Pharmaceuticals median is zero. Walter Schloss would see a marginal edge that could be expanded upon.
4.40%
Operating income growth of 4.40% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest advantage that can expand.
-2.80%
Negative net income growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate factors dragging net income down.
-2.81%
Negative EPS growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-2.81%
Negative diluted EPS growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
-0.00%
Share reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see a relative advantage if others are diluting.
-0.00%
Diluted share reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see an advantage if others are still diluting.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
55.34%
10Y revenue/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 15.77%. Joel Greenblatt would verify if a unique moat or brand fosters outperformance over a decade.
55.34%
5Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 27.32%. Joel Greenblatt would see if the company’s moat drives rapid mid-term expansion.
55.34%
3Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 10.42%. Joel Greenblatt might see a short-term competitive advantage at play.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
152.68%
Net income/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 62.63% over a decade. Joel Greenblatt might see a standout compounder of earnings.
152.68%
5Y net income/share CAGR > 1.5x Medical - Pharmaceuticals median of 48.12%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
152.68%
3Y net income/share CAGR > 1.5x Medical - Pharmaceuticals median of 33.04%. Joel Greenblatt might see a recent surge from market share gains or cost synergy.
82.37%
Equity/share CAGR of 82.37% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
82.37%
5Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 9.12%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
82.37%
3Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 17.20%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.19%
Decreasing inventory while Medical - Pharmaceuticals is rising. Seth Klarman might see an efficiency advantage or possibly a sign of weaker sales future.
-2.57%
Assets shrink while Medical - Pharmaceuticals median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
4.07%
BV/share growth of 4.07% while Medical - Pharmaceuticals is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
-13.18%
Debt is shrinking while Medical - Pharmaceuticals median is rising. Seth Klarman might see an advantage if growth remains possible.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.